Tag Archive for: life sciences

Sofinnova Partners raises €1.2 billion to fuel the next wave of life sciences innovation

Leading European venture capital firm exceeds €4 billion in assets under management, doubling its AUM in the last five years PARIS, France – March 4, 2025 — Sofinnova Partners (“Sofinnova”), a leading European venture capital firm in life sciences based in Paris, London, and Milan, today announced it had raised €1.2 billion across its platform […]

Hot topic: Why it’s best not to ‘go it alone’ with GLP-1 weight loss drugs

OZEMPIC, Wegovy, Mounjaro, Zepbound: they’ve quickly become part of our vocabulary.  In just a few years, powerful GLP-1 drugs, first introduced to control Type 2 diabetes but now much better known for their ability to help people rapidly lose weight, have become indispensable weapons in the Battle of the Bulge.  In the UK alone, some […]

AI makes headlines again as Insilico signs another major licensing deal

#AI has been making the headlines again this week, with a bold announcement from the UK government that it could be used to fix the many potholes that pepper Britain’s roads.  But beyond politics, there’s an ongoing narrative in life sciences about the growing role of AI across the clinical development process.  Perhaps the most […]

The must attend healthcare conferences in Winter/Spring 2025

Where has the time gone? We are now in 2025, and industry events are quickly approaching.   If you are still gathering your thoughts on how best to maximise your events calendar this year, allow us to flag some of the ‘must-attend’ Healthcare conferences of Winter/Spring 2025.     January is for JPM   The 43rd JPM Annual Healthcare […]

Weekly round-up: Ottimo Pharma Raises over $140 Million in Series A Financing 

Ottimo Pharma, a private biotech company pioneering bifunctional medicines to extend the lives of people living with cancer, on Thursday announced the completion of a Series A financing round of over $140 million. The financing will accelerate the lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for multiple solid tumour indications, in both IV and […]